JP Morgan Maintains Neutral on Afya, Lowers Price Target to $21
Afya Ltd (NASDAQ:AFYA) Passes Stringent 'Caviar Cruise' Quality Screen with Exceptional Growth and Value Metrics
AFYA vs. APEI: Which Stock Is the Better Value Option?
Afya Limited Releases 2025 Integrated Report
Afya's Recent National Exam Scores Are Worrying
Afya Limited (the "Company") Notice of Annual General Meeting of the Company
Afya (NasdaqGS:AFYA) Valuation Check As Shares Trade Near Recent Levels
Should Value Investors Buy Afya (AFYA) Stock?
Wall Street Analysts Predict a 25.57% Upside in Afya (AFYA): Here's What You Should Know
AFYA LTD-CLASS A (NASDAQ:AFYA): A Caviar Cruise Quality Screen Standout
Are Investors Undervaluing Afya (AFYA) Right Now?
Afya Ltd (AFYA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Competitive ...
Reported earlier, Afya Affirms FY2026 Sales Guidance of $731.710M-$759.496M vs $760.310M Est
Reported Earlier, Afya Q1 EPS $0.55 Beats $0.54 Estimate, Sales $192.330M Beat $191.870M Estimate
Afya Limited Announces First-Quarter 2026 Financial Results
Afya Limited (AFYA) Q1 2026 Earnings Call Transcript
Afya Limited 2026 Q1 - Results - Earnings Call Presentation
Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook
Assessing Afya (NasdaqGS:AFYA) Valuation After Recent Share Price Weakness
JP Morgan Maintains Neutral on Afya, Lowers Price Target to $21.5
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.